Address pain, deter abuse and safeguard patients
Pain trial regulations include extensive safety evaluations to determine tolerance levels, withdrawal and rebound effects and assessment of potential abuse, dependence or misuse. At the same time, increased prevalence of conditions such as osteoarthritis, chronic low back pain, diabetic peripheral neuropathic pain and post herpetic neuralgia is driving demand for tolerable and effective analgesics with abuse-deterrent formulations.
Expertise at the ready
Our Acute Care and Pain Center of Excellence houses approximately 650 team members experienced in the acute care and pain management market. They can help you meet safety needs as well as optimize product development potential.
With backgrounds in medical, operations, strategic planning and design, and early through late phase development, they represent a cross-functional team of therapeutic experts ready to take on your challenge.
Our experts can help maximize the possibilities for any type of pain trial, including neuropathic, nocioceptive, acute, chronic, oncologic and palliative care.
As you take on challenges like developing more effective treatments for neuropathic pain, producing abuse-deterrent opioids or managing intractable severe pain in cancer patients, QuintilesIMS will provide guidance and insight needed to support a better, safer end product. QuintilesIMS has the answers you need.